Tolerance to Opioid-Induced Respiratory Depression in Chronic High-Dose Opioid Users: A Model-Based Comparison With Opioid-Naïve Individuals

Marijke Hyke Algera, Erik Olofsen, Laurence Moss, Robert L Dobbins, Marieke Niesters, Monique van Velzen, Geert Jan Groeneveld, Jules Heuberger, Celine M Laffont, Albert Dahan, Marijke Hyke Algera, Erik Olofsen, Laurence Moss, Robert L Dobbins, Marieke Niesters, Monique van Velzen, Geert Jan Groeneveld, Jules Heuberger, Celine M Laffont, Albert Dahan

Abstract

Chronic opioid consumption is associated with addiction, physical dependence, and tolerance. Tolerance results in dose escalation to maintain the desired opioid effect. Intake of high-dose or potent opioids may cause life-threatening respiratory depression, an effect that may be reduced by tolerance. We performed a pharmacokinetic-pharmacodynamic analysis of the respiratory effects of fentanyl in chronic opioid users and opioid-naïve subjects to quantify tolerance to respiratory depression. Fourteen opioid-naïve individuals and eight chronic opioid users received escalating doses of intravenous fentanyl (opioid-naïve subjects: 75-350 µg/70 kg; chronic users: 250-700 µg/70 kg). Isohypercapnic ventilation was measured and the fentanyl plasma concentration-ventilation data were analyzed using nonlinear mixed-effects modeling. Apneic events occurred in opioid-naïve subjects after a cumulative fentanyl dose (per 70 kg) of 225 (n = 3) and 475 µg (n = 6), and in 7 chronic opioid users after a cumulative dose of 600 (n = 2), 1,100 (n = 2), and 1,800 µg (n = 3). The time course of fentanyl's respiratory depressant effect was characterized using a biophase equilibration model in combination with an inhibitory maximum effect (Emax ) model. Differences in tolerance between populations were successfully modeled. The effect-site concentration causing 50% ventilatory depression, was 0.42 ± 0.07 ng/mL in opioid-naïve subjects and 1.82 ± 0.39 ng/mL in chronic opioid users, indicative of a 4.3-fold sensitivity difference. Despite higher tolerance to fentanyl-induced respiratory depression, apnea still occurred in the opioid-tolerant population indicative of the potential danger of high-dose opioids in causing life-threatening respiratory depression in all individuals, opioid-naïve and opioid-tolerant.

Conflict of interest statement

R.L.D. and C.M.L. are employees of Indivior and declare no other competing interests. All other authors declared no competing interests for this work.

© 2020 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.

Figures

Figure 1
Figure 1
Example of effect of three fentanyl administrations (75 µg/70 kg, 150 µg/70 kg, and 250 µg/70 kg) on isohypercapnic ventilation in an opioid‐naïve individual (subject #110). Top panel: The measured fentanyl plasma concentrations (Conc.). Middle panel: 1‐minute ventilation averages (blue symbols = spontaneous breathing, red symbols = stimulated breathing during a 12‐minute apneic period following the third fentanyl administration) and end‐tidal CO2 concentration (green line); bottom panel: oxygen saturation (SpO2).
Figure 2
Figure 2
Best, median, and worst pharmacodynamic data fits (based on the coefficient of determination, R2) in opioid‐naïve subjects (a–c) and chronic opioid users (d–f). Blues dots are the 1‐minute averages of the measured breath‐to‐breath ventilation data; the red line is the data fit. The black triangles indicate the time of the intravenous fentanyl administrations.
Figure 3
Figure 3
Prediction‐corrected and variability‐corrected visual predictive checks of the pharmacodynamic model in opioid‐naïve subjects (a) and chronic opioid users (b). The dots are the 1‐minute ventilation averages. The continuous blue line is the simulated median, the thick broken blue line is the 95% confidence interval of the simulated median, and the thin dotted blue line is the simulated 2.5th and 97.5th percentiles. The continuous orange line is the measured median ventilation and the thin broken orange line is the measured 2.5th and 97.5th percentiles. Probability of apnea in opioid‐naïve subjects (c) and chronic opioid users (d). The red symbols are the probabilities of the observed apneic episodes; the yellow areas are the simulated 95% confidence intervals of the probability of apnea.
Figure 4
Figure 4
The probability of apnea in opioid‐naïve subjects (a) and chronic opioid users (b) for nine intravenous fentanyl doses: 1 = 75 µg/70 kg, 2 = 150 µg/70 kg, 3 = 250 µg/70 kg, 4 = 350 µg/70 kg, 5 = 500 µg/70 kg, 6 = 700 µg/70 kg, 7 = 1,000 µg/70 kg, 8 = 1,500 µg/70 kg, and 9 = 2,000 µg/70 kg. In chronic opioid users, the probability of apnea at doses < 500 µg/70 kg is < 1%.
Figure 5
Figure 5
Steady‐state plasma concentration‐isohypercapnic ventilation relationships in opioid‐naïve subjects (a) and chronic opioid users (b) with 90% prediction intervals indicating that there is a probability of apnea in opioid‐naïve subjects but not in chronic opioid users over the steady‐state concentration range of 0–3 ng/mL. Simulations of the effect of an intravenous fentanyl injection of 250 µg (c) and 1,000 µg (d) in a population of opioid‐naïve individuals and chronic opioid users, respectively (at a reference weight of 70 kg), on isohypercapnic ventilation. The band around the median values represents 90% prediction intervals. Opioid‐naïve individuals have a higher probability of apnea that lasts longer after 250 µg fentanyl (probability = 13%) than chronic opioid users after 1,000 µg (probability = 7%).

References

    1. Williams, J.T. et al. Regulation of mu‐opioid receptors: desensitization, phosphorylation, internalization, and tolerance. Pharmacol. Rev. 65, 223–254 (2013).
    1. Kreek, M.J. , Reed, B. & Butelman, E.R. Current status of opioid addiction treatment and related preclinical research. Sci. Adv. 5, eaax9140 (2019).
    1. Freye, E. & Latasch, L. Development of opioid tolerance – molecular mechanisms and clinical consequences. Anasthesiol. Intensivmed. Notfallmed. Schmerzther. 38, 14–26 (2003).
    1. Colvin, L.A. , Bull, F. & Hales, T.G. Perioperative opioid analgesia‐when is enough too much? A review of opioid‐induced tolerance and hyperalgesia. Lancet 393, 1558–1568 (2019).
    1. Martyn, J.A.J. , Mao, J. & Bittner, E.A. Opioid tolerance in critical illness. N. Engl. J. Med. 380, 365–378 (2019).
    1. Dahan, A. , Aarts, L. & Smith, T.W. Incidence, reversal, and prevention of opioid‐induced respiratory depression. Anesthesiology 112, 226–238 (2010).
    1. Emery, M.J. , Groves, C.C. , Kruse, T.N. , Shi, C. & Terman, G.W. Ventilation and the response to hypercapnia after morphine in opioid‐naive and opioid‐tolerant rats. Anesthesiology 124, 945–957 (2016).
    1. Mohammed, W. et al. Comparison of tolerance to morphine‐induced respiratory and analgesic effects in mice. Toxicol. Lett. 217, 251–259 (2013).
    1. Greenwald, M.K. Effects of opioid dependence and tobacco use on ventilatory response to progressive hypercapnia. Pharmacol. Biochem. Behav. 77, 39–47 (2004).
    1. Walsh, T.D. , Rivera, N.I. & Kaiko, R. Oral morphine and respiratory function amongst hospice inpatients with advanced cancer. Support. Care Cancer 11, 780–784 (2003).
    1. Santiago, T.V. , Pugliese, A.C. & Edelman, N.H. Control of breathing during methadone addiction. Am. J. Med. 62, 347–354 (1977).
    1. Moss, L. et al.Sustained high plasma buprenorphine concentrations inhibit respiratory effects of intravenous fentanyl in opioid‐tolerant individuals. Submitted.
    1. Wiest, K. , Algera, M.H. , Moss, L. , van Velzen, M. & Dobbins, R. High plasma buprenorphine concentrations decrease respiratory effects of intravenous fentanyl [poster]. Presented at the Annual Meeting of the American Society of Addiction Medicine; April 4–7, 2019; Orlando, FL.
    1. Dahan, A. , Nieuwenhuijs, D. & Teppema, L. Plasticity of central chemoreceptors: effect of bilateral carotid body resection on central CO2 sensitivity. PLoS Med 4, e239 (2007).
    1. Dahan, A. , DeGoede, J. , Berkenbosch, A. & Olievier, I.C. The influence of oxygen on the ventilatory response to carbon dioxide in man. J. Physiol. 428, 485–499 (1990).
    1. Anderson, B.J. & Holford, N.H. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab. Pharmacokinet. 24, 25–36 (2009).
    1. Yassen, A. et al. Mechanism‐based PK/PD modeling of the respiratory depressant effect of buprenorphine and fentanyl in healthy volunteers. Clin. Pharmacol. Ther. 81, 50–58 (2007).
    1. Olofsen, E. et al. Naloxone reversal of morphine‐ and morphine‐6‐glucuronide‐induced respiratory depression in healthy volunteers: a mechanism‐based pharmacokinetic‐pharmacodynamic modeling study. Anesthesiology 112, 1417–1427 (2010).
    1. Bergstrand, M. , Hooker, A.C. , Wallin, J.E. & Karlsson, M.O. Prediction‐corrected visual predictive checks for diagnosing nonlinear mixed‐effects models. AAPS J. 13, 143–151 (2011).
    1. Comets, E. , Brendel, K. & Mentre, F. Model evaluation in nonlinear mixed effect models, with applications to pharmacokinetics. J. Soc. Fr. Statistique. 151, 106–128 (2010).
    1. Mercer, S.L. & Coop, A. Opioid analgesics and P‐glycoprotein efflux transporters: a potential systems‐level contribution to analgesic tolerance. Curr. Top Med. Chem. 11, 1157–1164 (2011).
    1. Holmquist, G.L. Opioid metabolism and effects of cytochrome P450. Pain Med. 10(suppl. 1), S20–S29 (2009).
    1. Labroo, R.B. , Paine, M.F. , Thummel, K.E. & Kharasch, E.D. Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, efficacy, and drug interactions. Drug Metab. Dispos. 25, 1072–1080 (1997).
    1. Yu, C. , Yuan, M. , Yang, H. , Zhuang, X. & Li, H. P‐Glycoprotein on blood‐brain barrier plays a vital role in fentanyl brain exposure and respiratory toxicity in rats. Toxicol. Sci. 164, 353–362 (2018).
    1. Hill, R. et al. Ethanol reversal of tolerance to the respiratory depressant effects of morphine. Neuropsychopharmacology 41, 762–773 (2016).
    1. Hickman, M. , Lingford‐Hughes, A. , Bailey, C. , Macleod, J. , Nutt, D. & Henderson, G. Does alcohol increase the risk of overdose death: the need for a translational approach. Addiction 103, 1060–1062 (2008).
    1. Levine, B. , Green, D. & Smialek, J.E. The role of ethanol in heroin deaths. J. Forensic Sci. 40, 808–810 (1995).
    1. White, J.M. & Irvine, R.J. Mechanisms of fatal opioid overdose. Addiction 94, 961–972 (1999).
    1. Bukten, A. , Riksheim Stavesth, M. , Skurtveit, S. , Tverdal, A. , Strang, J. & Clausen, T. High risk of overdose death following release from prison: variations in mortality during a 15‐year observation period. Addiction 112, 1432–1439 (2017).
    1. Dahan, A. , Nieuwenhuijs, D. , Olofsen, E. , Sarton, E. , Romberg, R. & Teppema, L. Response surface modeling of alfentanil‐sevoflurane interaction on cardiorespiratory control and bispectral index. Anesthesiology 94, 982–991 (2001).
    1. Romberg, R. , Olofsen, E. , Sarton, E. , Teppema, L. & Dahan, A. Pharmacodynamic effect of morphine‐6‐glucuronide versus morphine on hypoxic and hypercapnic breathing in healthy volunteers. Anesthesiology 99, 788–798 (2003).
    1. Boom, M. et al. Fentanyl utility function: a risk‐benefit composite of pain relief and breathing responses. Anesthesiology 119, 663–674 (2013).
    1. van der Schrier, R. et al. Influence of ethanol on oxycodone‐induced respiratory depression: a dose‐escalating study in young and elderly individuals. Anesthesiology 126, 534–542 (2017).

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する